Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      AtomVie Global Radiopharma e ITM suscriben un acuerdo de suministro para lutecio-177 n.c.a.

      • USA - English
      • USA - Français
      • USA - English

      News provided by

      AtomVie Global Radiopharma Inc.

      Nov 19, 2026, 13:32 ET

      Share this article

      Share this article


      HAMILTON, ON y GARCHING, Alemania, 19 de noviembre de 2026 /PRNewswire/ -- AtomVie Global Radiopharma (AtomVie), una organización de desarrollo y fabricación por contrato (CDMO) de radiofármacos, e ITM Isotope Technologies Munich SE (ITM), una destacada empresa biotecnológica especializada en radiofármacos, han anunciado hoy un acuerdo de suministro para el radioisótopo de uso médico de alta calidad de ITM: lutecio-177 sin portador añadido (n.c.a. 177Lu). Según los términos del acuerdo, ITM suministrará n.c.a. 177Lu para respaldar las actividades de CDMO de AtomVie destinadas a empresas de radiofármacos; esto refuerza la cadena de suministro de AtomVie y brinda a sus socios en el ámbito de la oncología de precisión un mayor acceso a este radioisótopo de uso generalizado.

      Continue Reading
      AtomVie Global Radiopharma and ITM Enter Supply Agreement for n.c.a. Lutetium-177
      AtomVie Global Radiopharma and ITM Enter Supply Agreement for n.c.a. Lutetium-177

      «AtomVie presta servicios a diversas empresas radiofarmacéuticas en todo el sector, las cuales dependen de un suministro fiable de radioisótopos de alta calidad», afirmó Bruno Paquin, consejero delegado de AtomVie. «Al fortalecer esta relación con ITM, líder mundial en la producción de isótopos, tanto nosotros como nuestros socios actuales y futuros contamos con un acceso fiable al 177Lu sin portador añadido (n.c.a.) para respaldar programas de desarrollo de terapias y diagnósticos».

      El 177Lu n.c.a. (sin portador añadido) de ITM está diseñado para combinarse con moléculas dirigidas que transportan el radioisótopo directamente a los focos tumorales. Una vez allí, esta forma de lutecio-177 de alta pureza emite radiación beta terapéutica que destruye las células cancerosas de manera altamente localizada y precisa. ITM cuenta con un «Drug Master File» (DMF) —expediente maestro de fármaco— registrado ante la Administración de Alimentos y Medicamentos (FDA) de Estados Unidos para su 177Lu n.c.a., y dispone de autorización de comercialización en la Unión Europea (bajo la marca EndolucinBeta®).

      «Consideramos este acuerdo con AtomVie —un socio de confianza para las empresas que desarrollan radiofármacos nuevos e innovadores— como una muestra de cómo prestamos servicio al sector a través de nuestra red global de producción y suministro. Garantizar que nuestros socios cuenten con un acceso fiable a radioisótopos de alta calidad, incluido el lutecio-177, es una prioridad para nosotros. Junto con AtomVie y su red de desarrolladores de radiofármacos, ITM se enorgullece de contribuir a ampliar aún más el impacto de la terapia radiofarmacéutica en personas que padecen cáncer», añadió el doctor Andrew Cavey, consejero delegado de ITM.

      Acerca de AtomVie Global Radiopharma

      AtomVie Global Radiopharma Inc. es una organización líder a nivel mundial dedicada al desarrollo y la fabricación por contrato (CDMO), enfocada en impulsar el desarrollo y la comercialización de radiofármacos. AtomVie ofrece soluciones integrales que abarcan el desarrollo de procesos y métodos analíticos, la fabricación bajo normas de correcta fabricación (GMP), el control de calidad, el apoyo normativo y servicios de distribución global para productos farmacéuticos destinados a uso clínico o comercial. AtomVie brinda respaldo a empresas farmacéuticas y biotecnológicas de todo el mundo que desarrollan terapias y diagnósticos innovadores basados en la radiación; actualmente, la compañía se encuentra poniendo en marcha sus nuevas instalaciones de vanguardia, con una superficie de 72.300 pies cuadrados, ubicadas en Hamilton, Ontario.

      Para obtener más información, visite www.atomvie.com.

      Acerca de ITM Isotope Technologies Munich SE

      ITM, una empresa biotecnológica líder en el sector radiofarmacéutico, se dedica a ofrecer una nueva generación de terapias y diagnósticos radiofarmacéuticos para tumores de difícil tratamiento. Nuestro objetivo es satisfacer las necesidades de los pacientes oncológicos, los profesionales clínicos y nuestros socios mediante la excelencia en el desarrollo, la producción y el suministro global de radioisótopos médicos. Con el beneficio para el paciente como principio rector de todas nuestras actividades, ITM impulsa una amplia cartera de proyectos en oncología de precisión —que incluye múltiples estudios de fase 3—, combinando los radioisótopos de alta calidad de la compañía con diversas moléculas dirigidas. Aprovechando nuestras dos décadas de experiencia pionera en radiofarmacia, nuestra posición central en el sector y nuestra consolidada red global, ITM trabaja para proporcionar a los pacientes tratamientos dirigidos más eficaces, con el fin de mejorar los resultados clínicos y su calidad de vida. www.itm-radiopharma.com 

      Contacto en AtomVie: Para consultas de los medios, póngase en contacto con: Tina Chainani, teléfono: +1 905 912 4209, correo electrónico: [email protected]; Contacto en ITM: Comunicación corporativa: Kathleen Noonan/Julia Westermeir, teléfono: +49 89 329 8986 1500, correo electrónico: [email protected]; Relaciones con inversores: Ben Orzelek, teléfono: +49 89 329 8986 1009, correo electrónico: [email protected]

      Modal title

      Also from this source

      AtomVie Global Radiopharma et ITM concluent un accord d'approvisionnement pour du lutétium-177 n.c.a.

      AtomVie Global Radiopharma et ITM concluent un accord d'approvisionnement pour du lutétium-177 n.c.a.

      AtomVie Global Radiopharma (AtomVie), une organisation de développement et de fabrication à façon de produits radiopharmaceutiques (CDMO), et ITM...

      AtomVie Global Radiopharma and ITM Enter Supply Agreement for n.c.a. Lutetium-177

      AtomVie Global Radiopharma and ITM Enter Supply Agreement for n.c.a. Lutetium-177

      AtomVie Global Radiopharma (AtomVie), a radiopharmaceutical contract development and manufacturing organization (CDMO) and ITM Isotope Technologies...

      More Releases From This Source

      Explore

      Pharmaceuticals

      Pharmaceuticals

      Health Care & Hospitals

      Health Care & Hospitals

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Biotechnology

      Biotechnology

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.